Back to substance, then -- per Linda Johnson, for the AP, reporting:
. . . .Citigroup analyst John Boris said in a research note that. . . about 40 percent of [Merck's] global 2008 sales are from drugs losing patent protection in the next few years. . . .
He said keys will be whether sales of the cholesterol drugs Merck and Schering-Plough sell together decline further due to the controversy over their effectiveness, how much impact the weak allergy season and generic Zyrtec have on sales of Singulair, and whether sales of Gardisil go up or down. . . .
My earlier comments, quoting CS's Catherine Arnold, are here -- Barclays comments here. We shall see, but I expect currency headwinds to seriously dampen Schering-Plough's report -- by a little more than 10 percentage points.
No comments:
Post a Comment